Decentralized Clinical Trials Driving Economic Value In Clinical Development
Decentralized Clinical Trials: Driving Economic Value In Clinical Development
Sponsored by:
ICON
Sponsored by:
ICON
More from R&D
• By
Regenxbio reported functional and biomarker data from an ongoing study of RGX-202, which it hopes to file for approval in Duchenne muscular dystrophy in 2026.
• By
Gilead’s Kite division presented Phase I data for its next-generation CAR-T therapy KITE-363 in patients with B-cell lymphomas.
• By
EFPIA says reforms make the continent less attractive for innovative firms.
• By
J&J presented data at the American Society of Clinical Oncology meeting showing more than five-year disease- and therapy-free survival, but a myeloma working group will need to define what makes a cure.
More from Scrip
In partnership with
Insights from Novotech on Evolving Trends Impacting Global Clinical Development
Sponsored by:
Delve into the challenges facing the NHS, from rising medicine costs to supply shortages, and how generics and branded generics can provide solutions for a more sustainable healthcare system
Sponsored by:
Learn about the critical role the right CRO plays in successfully navigating the significant drug development opportunities in Japan.
Sponsored by:
Access key stats from biotechs on the latest trends impacting oncology R&D, including therapeutic pipelines and clinical trial challenges, AI/ML, and a future outlook on innovation.